Cargando…

Improvement of solubility and pharmacokinetic profile of hepatoprotector icariin through complexation with HP-γ-cyclodextrin

Icariin as a hepatoprotector from Herba epimedii can expand the cardiovascular and cerebral blood vessels, promote hematopoietic functions, enhance the immune system and show anti-liver tumor activities. However, its low solubility (0.02 mg/mL) limits its clinical applications as food and medical su...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Yili, Yu, Bo, Zhou, Shuzhen, Ding, Charles, Zhang, Zhiyuan, Xu, Shufeng, Xu, Zhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073486/
https://www.ncbi.nlm.nih.gov/pubmed/37033648
http://dx.doi.org/10.3389/fphar.2023.1138686
_version_ 1785019577429655552
author Ding, Yili
Yu, Bo
Zhou, Shuzhen
Ding, Charles
Zhang, Zhiyuan
Xu, Shufeng
Xu, Zhe
author_facet Ding, Yili
Yu, Bo
Zhou, Shuzhen
Ding, Charles
Zhang, Zhiyuan
Xu, Shufeng
Xu, Zhe
author_sort Ding, Yili
collection PubMed
description Icariin as a hepatoprotector from Herba epimedii can expand the cardiovascular and cerebral blood vessels, promote hematopoietic functions, enhance the immune system and show anti-liver tumor activities. However, its low solubility (0.02 mg/mL) limits its clinical applications as food and medical supplements. Through complexation with HP-γ-cyclodextrin by using a trace amount of water-soluble polymer, the water solubility of icariin was increased by 654 times, which is the best result to date for the water solubility study of icariin. In an in vitro pharmacokinetic study, the complexation increased the dissolution rate of icariin by 80 times, and the icariin complex can be 100% released in the first few minutes. Through complexation, in an in vivo dog pharmacokinetic study, the C ( max ) of icariin was increased about 5 times, the AUC(0-120) was increased about 20 times and the clearance of icariin was changed from 11.17 L/h/kg to 0.65 L/h/kg. The half-life time was changed from 0.68 h to 6.38 h and the relative bioavailability was increased by nearly 20 times, indicating that less drug is needed for the same therapeutic effect by using the icariin complex, and the complex can be used as a potential potent hepatoprotector or anti-liver cancer drug.
format Online
Article
Text
id pubmed-10073486
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100734862023-04-06 Improvement of solubility and pharmacokinetic profile of hepatoprotector icariin through complexation with HP-γ-cyclodextrin Ding, Yili Yu, Bo Zhou, Shuzhen Ding, Charles Zhang, Zhiyuan Xu, Shufeng Xu, Zhe Front Pharmacol Pharmacology Icariin as a hepatoprotector from Herba epimedii can expand the cardiovascular and cerebral blood vessels, promote hematopoietic functions, enhance the immune system and show anti-liver tumor activities. However, its low solubility (0.02 mg/mL) limits its clinical applications as food and medical supplements. Through complexation with HP-γ-cyclodextrin by using a trace amount of water-soluble polymer, the water solubility of icariin was increased by 654 times, which is the best result to date for the water solubility study of icariin. In an in vitro pharmacokinetic study, the complexation increased the dissolution rate of icariin by 80 times, and the icariin complex can be 100% released in the first few minutes. Through complexation, in an in vivo dog pharmacokinetic study, the C ( max ) of icariin was increased about 5 times, the AUC(0-120) was increased about 20 times and the clearance of icariin was changed from 11.17 L/h/kg to 0.65 L/h/kg. The half-life time was changed from 0.68 h to 6.38 h and the relative bioavailability was increased by nearly 20 times, indicating that less drug is needed for the same therapeutic effect by using the icariin complex, and the complex can be used as a potential potent hepatoprotector or anti-liver cancer drug. Frontiers Media S.A. 2023-03-22 /pmc/articles/PMC10073486/ /pubmed/37033648 http://dx.doi.org/10.3389/fphar.2023.1138686 Text en Copyright © 2023 Ding, Yu, Zhou, Ding, Zhang, Xu and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ding, Yili
Yu, Bo
Zhou, Shuzhen
Ding, Charles
Zhang, Zhiyuan
Xu, Shufeng
Xu, Zhe
Improvement of solubility and pharmacokinetic profile of hepatoprotector icariin through complexation with HP-γ-cyclodextrin
title Improvement of solubility and pharmacokinetic profile of hepatoprotector icariin through complexation with HP-γ-cyclodextrin
title_full Improvement of solubility and pharmacokinetic profile of hepatoprotector icariin through complexation with HP-γ-cyclodextrin
title_fullStr Improvement of solubility and pharmacokinetic profile of hepatoprotector icariin through complexation with HP-γ-cyclodextrin
title_full_unstemmed Improvement of solubility and pharmacokinetic profile of hepatoprotector icariin through complexation with HP-γ-cyclodextrin
title_short Improvement of solubility and pharmacokinetic profile of hepatoprotector icariin through complexation with HP-γ-cyclodextrin
title_sort improvement of solubility and pharmacokinetic profile of hepatoprotector icariin through complexation with hp-γ-cyclodextrin
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073486/
https://www.ncbi.nlm.nih.gov/pubmed/37033648
http://dx.doi.org/10.3389/fphar.2023.1138686
work_keys_str_mv AT dingyili improvementofsolubilityandpharmacokineticprofileofhepatoprotectoricariinthroughcomplexationwithhpgcyclodextrin
AT yubo improvementofsolubilityandpharmacokineticprofileofhepatoprotectoricariinthroughcomplexationwithhpgcyclodextrin
AT zhoushuzhen improvementofsolubilityandpharmacokineticprofileofhepatoprotectoricariinthroughcomplexationwithhpgcyclodextrin
AT dingcharles improvementofsolubilityandpharmacokineticprofileofhepatoprotectoricariinthroughcomplexationwithhpgcyclodextrin
AT zhangzhiyuan improvementofsolubilityandpharmacokineticprofileofhepatoprotectoricariinthroughcomplexationwithhpgcyclodextrin
AT xushufeng improvementofsolubilityandpharmacokineticprofileofhepatoprotectoricariinthroughcomplexationwithhpgcyclodextrin
AT xuzhe improvementofsolubilityandpharmacokineticprofileofhepatoprotectoricariinthroughcomplexationwithhpgcyclodextrin